Pemetrexed
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Pemetrexed: From Established Oncology Indications to Malignant Peritoneal Mesothelioma
One-Sentence Summary
Pemetrexed is a multitargeted antifolate chemotherapy agent, with globally recognized use in non-small cell lung cancer and malignant pleural mesothelioma. The TxGNN model predicts it may also be effective for Malignant Peritoneal Mesothelioma, a rare and histologically related tumour, with 11 clinical trials and 20 publications currently supporting this direction — though no completed Phase 3 trial exists yet for this specific anatomical subtype.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Non-small cell lung cancer / Malignant pleural mesothelioma (established chemotherapy indications; no EU marketing-license record found in this dataset) |
| Predicted New Indication | Malignant Peritoneal Mesothelioma |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 |
| EU Market Status | Not Marketed (no license record in this dataset) |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for pemetrexed is not available in this dataset (data gap DG002). Based on well-established pharmacological knowledge, pemetrexed is a multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase — key folate-dependent enzymes required for de novo purine and pyrimidine synthesis. This mechanism underlies its proven efficacy, in combination with a platinum agent, in mesothelioma of pleural origin.
Malignant peritoneal mesothelioma and malignant pleural mesothelioma arise from the same mesothelial cell lineage and share nearly identical histological and molecular pathological features; they differ mainly in anatomical site of origin (pleura vs. peritoneum) rather than underlying tumour biology. Because pemetrexed’s antifolate mechanism is not organ-specific, its antiproliferative activity is expected to translate across mesothelial-derived tumours regardless of cavity of origin.
This mechanistic rationale is reinforced by direct clinical practice: cisplatin plus pemetrexed is already used as a de facto first-line regimen for peritoneal mesothelioma in oncology practice, extrapolated from the pleural mesothelioma evidence base (see rank-3 prediction in this same evidence pack, “Pleural Mesothelioma,” which carries an L1 evidence level with multiple completed Phase 3 RCTs). This existing extrapolation pattern supports the biological plausibility of the TxGNN prediction, even though peritoneal-specific trials remain at the Phase 1/2 stage.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06057935 | Phase 2 | Recruiting | 64 | Randomized trial comparing intraperitoneal vs. intravenous chemotherapy (incl. pemetrexed-based regimens) after cytoreductive surgery + HIPEC in malignant peritoneal mesothelioma |
| NCT00061477 | Phase 2 | Completed | 48 | Pemetrexed + gemcitabine as front-line chemotherapy in pleural or peritoneal mesothelioma; assessed safety, survival, and tumour response |
| NCT05001880 | Phase 2 | Recruiting | 66 | Randomized trial of carboplatin/pemetrexed/bevacizumab ± atezolizumab as neoadjuvant/palliative therapy for peritoneal mesothelioma |
| NCT03875144 | Phase 2 | Suspended | 66 | PIPAC + systemic chemotherapy (cisplatin + pemetrexed) vs. systemic chemotherapy alone as 1st-line treatment; primary endpoint overall survival |
| NCT06543069 | Phase 2 | Recruiting | 28 | Sintilimab + bevacizumab combined with pemetrexed and cisplatin in unresectable disease; exploring efficacy, safety, and biomarkers |
| NCT04462809 | Phase 2 | Unknown | 40 | Maintenance talazoparib following first-line platinum-based chemotherapy (incl. pemetrexed) in pleural or peritoneal mesothelioma |
| NCT02535312 | Phase 1/2 | Active, not recruiting | 30 | Methoxyamine (TRC102) combined with cisplatin and pemetrexed in advanced solid tumours/mesothelioma, including patients refractory to pemetrexed-cisplatin |
| NCT00402766 | Phase 1 | Completed | 19 | Cisplatin, pemetrexed, and imatinib in unresectable/metastatic mesothelioma; determined maximum tolerated dose |
| NCT02029690 | Phase 1 | Terminated | 85 | ADI-PEG 20 with pemetrexed and cisplatin in arginine-dependent tumours, including advanced peritoneal mesothelioma |
| NCT01353482 | Phase 1/2 | Withdrawn | 0 | Vorinostat with pemetrexed-cisplatin in mesothelioma (pleural/peritoneal); trial withdrawn before enrollment |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26941986 | 2016 | Review | Journal of gastrointestinal oncology | Overview of diagnosis and management of malignant peritoneal mesothelioma, including systemic chemotherapy role |
| 30450291 | 2018 | Review | Translational lung cancer research | Comprehensive review of peritoneal mesothelioma epidemiology, pathology, and treatment approaches |
| 35407498 | 2022 | Review | Journal of clinical medicine | Review of treatment strategies for malignant peritoneal mesothelioma, including systemic chemotherapy |
| 28594258 | 2017 | Retrospective study | Expert review of anticancer therapy | Evaluates efficacy of first-line pemetrexed + cisplatin specifically in malignant peritoneal mesothelioma |
| 31287877 | 2019 | Retrospective study | Japanese journal of clinical oncology | Assesses efficacy and safety of pemetrexed + cisplatin as first-line therapy in advanced peritoneal mesothelioma |
| 41710652 | 2026 | Retrospective cohort | Frontiers in oncology | Single-center study of pemetrexed/platinum ± bevacizumab after CRS+HIPEC in peritoneal mesothelioma |
| 38806763 | 2024 | Multi-center cohort | Annals of surgical oncology | Analysis of treatment strategies and outcomes across a multi-center peritoneal mesothelioma population |
| 34723916 | 2022 | Case series | Journal of immunotherapy | Combination chemoimmunotherapy in platinum-nonresponsive metastatic peritoneal mesothelioma |
| 31417959 | 2019 | Cohort/Case series | Pleura and peritoneum | Bidirectional chemotherapy enabling surgery and HIPEC in initially unresectable peritoneal mesothelioma |
| 23291819 | 2013 | Case report | BMJ case reports | Patient with peritoneal mesothelioma responding to rechallenge with cisplatin and pemetrexed, with literature review |
EU Market Information
No EU marketing authorizations for pemetrexed are recorded in this dataset (market status: Not Marketed; total licenses: 0). This appears to be a data-collection gap for this specific dataset rather than a confirmed absence from the EU market, since pemetrexed is a long-established oncology agent internationally. Regulatory license data should be verified directly against the EMA product database before any go/no-go decision is finalized.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (multitargeted antifolate class — inhibits thymidylate synthase, dihydrofolate reductase, and GARFT) |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions (no structured toxicity dataset available; antifolate/platinum combination regimens are generally associated with clinically significant myelosuppression) |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Complete blood count with differential, renal function (pemetrexed is renally cleared), folate/vitamin B12 status prior to and during treatment |
| Handling Protection | Standard cytotoxic drug handling precautions apply, consistent with antineoplastic antifolate agents |
Safety Considerations
Please refer to the SmPC for safety information. No structured key warnings, contraindications, or drug-drug interaction data are available in this evidence pack (DDI query status: not found); this is flagged as a Blocking data gap (DG001) that must be resolved before any Stage 1 safety review.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple Phase 1/2 trials (several actively recruiting) and a growing body of retrospective/cohort literature directly support pemetrexed + platinum-based regimens in malignant peritoneal mesothelioma, and this extrapolation is already reinforced by the much stronger, Phase 3-validated evidence base for pemetrexed in the closely related pleural mesothelioma indication. However, no completed Phase 3 RCT exists specifically for the peritoneal subtype, capping the evidence level at L2.
To proceed, the following is needed:
- TFDA/EMA product label warnings and contraindications (currently a Blocking data gap, DG001)
- Confirmed mechanism of action documentation from DrugBank (currently a High-severity data gap, DG002)
- Verification of actual EU marketing authorization status (dataset shows 0 licenses, which is inconsistent with pemetrexed’s known international approval history and should be re-queried)
- Monitoring of ongoing Phase 2 trials (e.g., NCT06057935, NCT05001880) for maturing efficacy and safety data specific to peritoneal mesothelioma
- A dedicated drug-drug interaction review, since the current DDI query returned no results
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.